Huahai Pharmaceutical announced that its subsidiary obtained clinical trial license for injectable HB0052.
华海药业：下属子公司获得注射用HB0052药物临床试验许可
Huahai Pharmaceutical: A subsidiary obtained clinical trial license for injectable HB0052
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.